

Table 1.22
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2010^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			35-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 35 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 35 Years ^d
All Sites	Both Sexes	4,511,266	4,598,344	5,044,168	12,600,627	12,810,577
	Male	2,332,050	2,366,640	2,584,260	5,990,343	6,060,178
	Female	2,179,216	2,231,704	2,459,908	6,610,284	6,750,399
Oral Cavity & Pharynx	Both Sexes	102,019	117,112	121,258	264,620	291,343
	Male	71,123	80,929	83,544	175,045	190,951
	Female	30,896	36,183	37,714	89,575	100,392
Esophagus	Both Sexes	21,268	25,973	26,092	33,702	39,594
	Male	16,808	20,399	20,447	26,317	30,715
	Female	4,460	5,574	5,645	7,385	8,879
Stomach	Both Sexes	35,420	42,280	42,609	70,821	81,142
	Male	21,286	25,765	25,901	40,560	46,844
	Female	14,134	16,515	16,708	30,261	34,298
Colon & Rectum	Both Sexes	407,833	471,251	480,046	1,129,666	1,258,620
	Male	207,302	239,824	244,132	561,245	622,211
	Female	200,531	231,427	235,914	568,421	636,409
Liver & Intrahepatic Bile Duct	Both Sexes	30,577	34,834	34,867	40,940	45,832
	Male	22,266	25,232	25,265	28,891	32,221
	Female	8,311	9,602	9,602	12,049	13,611
Pancreas	Both Sexes	31,442	38,275	38,275	41,284	49,174
	Male	15,733	19,467	19,467	20,155	24,367
	Female	15,709	18,808	18,808	21,129	24,807
Larynx	Both Sexes	30,947	37,152	37,518	87,135	98,063
	Male	25,107	30,036	30,356	70,117	78,586
	Female	5,840	7,116	7,162	17,018	19,477
Lung & Bronchus	Both Sexes	231,996	296,283	304,764	391,564	480,133
	Male	108,211	140,119	143,487	178,912	220,472
	Female	123,785	156,164	161,277	212,652	259,661
Melanoma of the Skin	Both Sexes	276,312	312,334	325,566	884,259	953,581
	Male	148,749	171,783	180,200	440,298	480,917
	Female	127,563	140,551	145,366	443,961	472,664
Breast	Female	842,193	909,424	965,835	2,770,060	2,934,536
Cervix	Female	38,963	40,783	40,907	208,065	213,819
Corpus & Uterus, NOS	Female	169,126	189,983	190,106	569,448	620,803
Ovary ^f	Female	57,207	66,063	66,139	169,398	190,511

^a U.S. 2010 cancer prevalence counts are based on 2010 cancer prevalence proportions from the SEER 9 registries and 1/1/2010 U.S. population estimates based on the average of 2009 and 2010 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 35 years (1975-2009)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2005-2009)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2005; Melanoma in 2006.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 35-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2010.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 35-year limited duration prevalence. The 2005 breast cancer is counted for the breast 5-year and 35-year limited duration prevalence.

In method (e) the 2005 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2006 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2010^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			35-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 35 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 35 Years ^d
Prostate	Male	1,026,391	1,107,903	1,107,977	2,616,190	2,787,286
Testis	Male	42,302	43,012	43,616	205,130	207,844
Urinary Bladder	Both Sexes	198,998	248,244	253,143	551,278	641,106
	Male	151,489	190,075	194,009	411,638	479,012
	Female	47,509	58,169	59,134	139,640	162,094
Kidney & Renal Pelvis	Both Sexes	145,766	177,066	179,051	330,450	385,370
	Male	88,557	108,930	110,317	196,335	230,734
	Female	57,209	68,136	68,734	134,115	154,636
Brain & Nervous System	Both Sexes	43,995	46,883	47,345	128,063	132,164
	Male	24,044	25,790	26,033	68,158	70,466
	Female	19,951	21,093	21,312	59,905	61,698
Thyroid	Both Sexes	165,253	183,524	184,093	494,969	528,131
	Male	37,076	42,905	43,058	107,747	117,569
	Female	128,177	140,619	141,035	387,222	410,562
Hodgkin Lymphoma	Both Sexes	39,048	41,589	41,611	168,309	172,937
	Male	21,122	22,557	22,568	87,084	89,522
	Female	17,926	19,032	19,043	81,225	83,415
Non-Hodgkin Lymphoma	Both Sexes	198,946	233,585	235,457	499,712	558,340
	Male	105,553	125,451	126,442	261,560	292,961
	Female	93,393	108,134	109,015	238,152	265,379
Myeloma	Both Sexes	49,451	58,292	58,328	77,360	88,490
	Male	26,622	32,063	32,087	42,092	48,802
	Female	22,829	26,229	26,241	35,268	39,688
Leukemia	Both Sexes	112,120	129,298	129,528	282,150	310,046
	Male	64,915	75,612	75,711	160,039	176,801
	Female	47,205	53,686	53,817	122,111	133,245
Acute Lymphocytic Leukemia	Both Sexes	16,205	16,686	16,686	66,030	66,759
	Male	9,215	9,443	9,443	36,418	36,708
	Female	6,990	7,243	7,243	29,612	30,051
Childhood (Ages 0-19)	Both Sexes	63,904	63,977	64,503	304,247	304,716
	Male	33,948	33,981	34,250	156,819	157,032
	Female	29,956	29,996	30,253	147,428	147,684
Kaposi Sarcoma	Both Sexes	7,319	7,750	7,750	24,815	25,977
	Male	6,865	7,208	7,208	23,533	24,518
	Female	454	542	542	1,282	1,459
Mesothelioma	Both Sexes	2,968	3,926	3,938	4,538	5,658
	Male	1,998	2,761	2,773	2,601	3,467
	Female	970	1,165	1,165	1,937	2,191

^a U.S. 2010 cancer prevalence counts are based on 2010 cancer prevalence proportions from the SEER 9 registries and 1/1/2010 U.S. population estimates based on the average of 2009 and 2010 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 35 years (1975-2009)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2005-2009)
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2005; Melanoma in 2006.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 35-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2010. In method (d) the 1981 melanoma is counted for the melanoma and all sites 35-year limited duration prevalence. The 2005 breast cancer is counted for the breast 5-year and 35-year limited duration prevalence. In method (e) the 2005 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2006 melanoma is counted for 5-year limited duration prevalence for melanoma.